

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM478115

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Reata Pharmaceuticals, Inc.		06/14/2018	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Oxford Finance LLC, as Collateral Agent		
Street Address:	133 North Fairfax Street		
City:	Alexandria		
State/Country:	VIRGINIA		
Postal Code:	22314		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Serial Number:	86778681	REATA PHARMACEUTICALS	
Serial Number:	86778679	REATA PHARMACEUTICALS	
Serial Number:	86778689	REATA	
Serial Number:	86778692	REATA	
Serial Number:	86778686		
CORRESPONDENCE DATA			
Fax Number:	8586385130		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	619-699-2700		
Email:	susan.reynholds@dlapiper.com		
Correspondent Name:	DLA Piper LLP (US)		
Address Line 1:	401 B Street, Suite 1700		
Address Line 4:	San Diego, CALIFORNIA 92101		
NAME OF SUBMITTER:	Matt Schwartz		
SIGNATURE:	/s/ Matt Schwartz		
DATE SIGNED:	06/14/2018		
Total Attachments: 8 source=IPSA#page1.tif			

CH \$140.00 86778681

source=IPSA#page2.tif
source=IPSA#page3.tif
source=IPSA#page4.tif
source=IPSA#page5.tif
source=IPSA#page6.tif
source=IPSA#page7.tif
source=IPSA#page8.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of June 14, 2018 by and between OXFORD FINANCE LLC, as collateral agent for the Lenders (the "Lenders") described in the Loan Agreement (as described below) (in such capacity, the "Collateral Agent") and REATA PHARMACEUTICALS, INC. ("Grantor").

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Amended and Restated Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated of even date herewith (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein and not otherwise defined herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

2. This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

REATA PHARMACEUTICALS, INC.

2801 Gateway Drive, Suite 150
Irving, TX 75063
Attn: Chief Financial Officer

By: 
Name: Jason D. Wilson
Title: Chief Financial Officer

COLLATERAL AGENT:

Address of Lender:

OXFORD FINANCE LLC

133 North Fairfax Street
Alexandria, Virginia 22314
Attn: Legal Department

By: _____
Name: _____
Title: _____

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

REATA PHARMACEUTICALS, INC.

2801 Gateway Drive, Suite 150
Irving, TX 75063
Attn: Chief Financial Officer


By: _____
Name: Jason D. Wilson
Title: Chief Financial Officer

COLLATERAL AGENT:

Address of Lender:

OXFORD FINANCE LLC

133 North Fairfax Street
Alexandria, Virginia 22314
Attn: Legal Department

By: 
Name: Colette H. Featherly
Title: Senior Vice President

[Signature Page to Intellectual Property Security Agreement]

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None

EXHIBIT B

Patents

<u>Description</u>	<u>Patent/App. No.</u>	<u>Issue/File Date</u>
Methods of treating obesity using antioxidant inflammation modulations	13085338	4/12/11
Novel forms of CDDO methyl ester	8088824	1/3/12
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	7915402	3/29/11
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives	7943778	5/17/11
Antioxidant inflammation modulators: novel derivatives of oleanolic acid	8071632	12/6/11
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	8124656	2/28/12
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	8124799	2/28/12
Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use	8258329	9/4/12
Novel forms of CDDO methyl ester	8309601	11/13/12
Antioxidant inflammation modulators: novel derivatives of oleanolic acid	8338618	12/25/12
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives	8394967	3/12/13
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	8440820	5/14/13
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	8440854	5/14/13
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	8513436	8/20/13
Novel forms of CDDO methyl ester	8633243	1/21/14
Delayed release, oral dosage compositions that contain amorphous CDDO-ME	8747901	6/10/14
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	8993640	3/31/15
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	9090574	7/28/15
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	9102681	8/11/15
Delayed release, oral dosage compositions that contain amorphous CDDO-ME	9155721	10/13/15
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	9174941	11/3/15

<u>Description</u>	<u>Patent/App. No.</u>	<u>Issue/File Date</u>
Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use	9233998	1/12/16
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives	9249089	2/2/16
C13-hydroxy derivatives of oleanolic acid and methods of use thereof	9278912	3/8/16
C4 monomethyl triterpenoid derivatives and methods of use thereof	9290536	3/22/16
Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	9464082	10/11/16
C17-heteroaryl derivatives of oleanolic acid and methods of use thereof	9512094	12/6/16
A-ring epoxidized triterpenoid-based antioxidant inflammation modulators and methods of use thereof	9556222	1/31/17
C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof	9593074	3/14/17
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	9670147	6/6/17
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	9701709	7/11/17
Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use	9796668	10/24/17
Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use	15791677	10/24/17
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	9884809	2/6/18
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	15861758	1/4/18
C17-heteroaryl derivatives of oleanolic acid and methods of use thereof	9889143	2/13/18
C17-heteroaryl derivatives of oleanolic acid and methods of use thereof	15861241	1/3/18
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	RE45288	12/9/14
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	RE45325	1/6/15
Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof	14466495	8/22/14
C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof	15433100	2/15/17
Imidazolyl tricyclic enones as antioxidant inflammation modulators	15548909	8/4/17

<u>Description</u>	<u>Patent/App. No.</u>	<u>Issue/File Date</u>
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	15615393	6/6/17
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	15622568	6/14/17
Synthetic triterpenoids and methods of use in the treatment of disease	8129429	3/6/12
Synthetic triterpenoids and methods of use in the treatment of disease	8455544	6/4/13
Synthetic triterpenoids and methods of use in the treatment of disease	9757359	9/12/17
Synthetic triterpenoids and methods of use in the treatment of disease	15675862	8/14/17
Betulinic acid derivative and method of use thereof	8778990	7/15/14
C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses	15760662	3/16/18
RORgammaT inverse agonists with an Indazole or Hexahydroindazole core	62660859	4/20/18
RORgammaT inverse agonists with an Indazole or Hexahydroindazole core	62660865	4/20/18
Pyridopyrazolopyrimidine Derivatives for the Treatment of Cystic Fibrosis	62674549	5/21/18
Co-crystal Forms of a Novobiocin Analog and Proline	62627570	2/7/18
Biaryl Amides with Modified Sugar Groups for Treatment of Diseases Associated with Heat Shock Protein Pathway	62671047	5/14/18
Methods of treating Alport Syndrome using Bardoxolone Methyl or Analogs Thereof	62535663	7/21/17
Methods of treating Alport Syndrome using Bardoxolone Methyl or Analogs Thereof	62580597	11/2/17

EXHIBIT C

Trademarks

<u>Description</u>	<u>Serial No.</u>	<u>File Date</u>
REATA PHARMACEUTICALS	86778681	10/5/15
REATA PHARMACEUTICALS	86778679	10/5/15
REATA	86778689	10/5/15
REATA	86778692	10/5/15
Design	86778686	10/5/15